Company intelligence / Profile preview

Aneuvas Technologies

Flagstaff, Arizona, United Statesdnb.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 1

Overview

Aneuvas Technologies is developing PPODA-QT, a novel neurovascular device for endovascular embolization of brain aneurysms. Preclinical studies have shown effective long-term occlusion in animal models and promotion of bioactive healing responses. The company has received NIH STTR Phase II funding to optimize the device for stability, biocompatibility, and FDA Investigational Device Exemption (IDE) submission.

Therapeutic areas: CardiovascularNeurology
Modalities: DevicePolymer-based embolic agent (PPODA-QT)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

PPODA-QT

Phase 2

Indications: Cerebral aneurysm

1 more asset in the full pipeline.

Request access →

Partnerships

NIH/NINDS via SBIR/STTR grants

Beyond the preview

Go deeper on Aneuvas Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aneuvas Technologies.

Explore the full profile